Chemistry:Terlipressin
 | |
| Clinical data | |
|---|---|
| Trade names | Terlivaz |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | ~30% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C52H74N16O15S2 |
| Molar mass | 1227.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Terlipressin, sold under the brand name Terlivaz among others, is an analogue of vasopressin used as a vasoactive drug in the management of low blood pressure. It has been found to be effective when norepinephrine does not help. Terlipressin is a vasopressin receptor agonist.[1]
Terlipressin was approved for medical use in the United States in 2022.[1][3][4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[4][5]
Medical uses
Terlipressin is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.[1]
Indications for use include norepinephrine-resistant septic shock[6] although, 2021 Surviving Sepsis Guidelines recommend against its use for adults with septic shock[7] and hepatorenal syndrome.[8] In addition, it is used to treat bleeding esophageal varices.[9]
Contraindications
Terlipressin is contraindicated in people experiencing hypoxia or worsening respiratory symptoms and in people with ongoing coronary, peripheral or mesenteric ischemia.[1] Terlipressin may cause fetal harm when used during pregnancy.[1]
Society and culture
Terlipressin is available in United States,[10] New Zealand,[11] Australia, the European Union,[12] India, Pakistan & UAE. It is sold under various brand names including Glypressin and Terlivaz.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Terlivaz- terlipressin injection, powder, lyophilized, for solution". 19 September 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a35b86c-f451-4fac-8499-43019e4da354.
- ↑ "Drug Approval Package: Terlivaz". U.S. Food and Drug Administration (FDA). 7 October 2022. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022231Orig1s000TOC.cfm.
- ↑ "Drug Approval Package: Terlivaz". 7 October 2022. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/022231Orig1s000TOC.cfm.
- ↑ 4.0 4.1 "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". 10 January 2023. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2022.
This article incorporates text from this source, which is in the public domain.
- ↑ (PDF) New Drug Therapy Approvals 2022 (Report). January 2024. https://www.fda.gov/media/164429/download. Retrieved 14 January 2024. This article incorporates text from this source, which is in the public domain.
- ↑ "Terlipressin for norepinephrine-resistant septic shock". Lancet 359 (9313): 1209–10. 2002. doi:10.1016/S0140-6736(02)08225-9. PMID 11955542.
- ↑ Evans, Laura; Rhodes, Andrew; Alhazzani, Waleed; Antonelli, Massimo; Coopersmith, Craig M.; French, Craig; Machado, Flávia R.; Mcintyre, Lauralyn et al. (November 2021). "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021" (in en-US). Critical Care Medicine 49 (11): e1063. doi:10.1097/CCM.0000000000005337. https://journals.lww.com/ccmjournal/fulltext/2021/11000/surviving_sepsis_campaign__international.21.aspx.
- ↑ "Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome". J Hepatol 33 (1): 43–8. 2000. doi:10.1016/S0168-8278(00)80158-0. PMID 10905585.
- ↑ Ioannou, George N, ed (2003). "Terlipressin for acute esophageal variceal hemorrhage". Cochrane Database Syst Rev (1): CD002147. doi:10.1002/14651858.CD002147. PMID 12535432.
- ↑ "FDA approves treatment to improve kidney function in adults with hepatorenal syndrome". FDA. 14 September 2022. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-improve-kidney-function-adults-hepatorenal-syndrome. Retrieved 2023-02-21.
- ↑ http://www.medsafe.govt.nz/profs/datasheet/g/Glypressin01mgmlFerringinj.pdf [bare URL PDF]
- ↑ "Terlipressin". https://www.drugs.com/international/terlipressin.html.
External links
- "Terlipressin". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/terlipressin.
 |  |
